Cadence Capital Management’s Travere Therapeutics TVTX Stock Holding History

Cadence Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$256K	Buy	+13,880	New	+$270K	0.06%	252

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cadence Capital Management's TVTX Position: Q3 2020 in Review

Cadence Capital Management opened a new position in Travere Therapeutics (TVTX) in Q3 2020: 13,880 shares worth $256K. The stake represents 0.06% of the portfolio and ranks #252 among its holdings.

134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

Cadence Capital Management held 13,880 shares of Travere Therapeutics worth $256K as of Q3 2020.
Travere Therapeutics was a new Cadence Capital Management position in Q3 2020.
Travere Therapeutics made up 0.06% of Cadence Capital Management's portfolio in Q3 2020, its #252 holding.
134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.